Compare Advance Auto Parts, Inc. (AAP) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Enveric Biosciences Inc — how do they compare? Advance Auto Parts, Inc. trades at $54.72 (market cap $3.37B), while Enveric Biosciences Inc trades at $1.42 (market cap $5.84M). The key difference: Advance Auto Parts, Inc. is far larger — about 577.1× Enveric Biosciences Inc's market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| AAP | ENVB | |
|---|---|---|
Market Cap | $3.37B | $5.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $17.40 |
52-Week Low | $38.75 | $1.28 |
Enterprise Value | $5.64B | $932.52K |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
